110 related articles for article (PubMed ID: 19171732)
1. Exenatide-associated ischemic renal failure.
Weise WJ; Sivanandy MS; Block CA; Comi RJ
Diabetes Care; 2009 Feb; 32(2):e22-3. PubMed ID: 19171732
[No Abstract] [Full Text] [Related]
2. Exenatide and renal failure.
Ferrer-Garcia JC; Martinez-Chanza N; Tolosa-Torréns M; Sánchez-Juan C
Diabet Med; 2010 Jun; 27(6):728-9. PubMed ID: 20546299
[No Abstract] [Full Text] [Related]
3. Acute renal failure when exenatide is co-administered with diuretics and angiotensin II blockers.
López-Ruiz A; del Peso-Gilsanz C; Meoro-Avilés A; Soriano-Palao J; Andreu A; Cabezuelo J; Arias JL
Pharm World Sci; 2010 Oct; 32(5):559-61. PubMed ID: 20686848
[TBL] [Abstract][Full Text] [Related]
4. Effects of exenatide on kidney function, adverse events, and clinical end points of kidney disease in type 2 diabetes.
Tuttle KR; Heilmann C; Hoogwerf BJ; Brown C; Anderson PW
Am J Kidney Dis; 2013 Aug; 62(2):396-8. PubMed ID: 23684754
[No Abstract] [Full Text] [Related]
5. Exenatide may aggravate moderate diabetic renal impairment: a case report.
Johansen OE; Whitfield R
Br J Clin Pharmacol; 2008 Oct; 66(4):568-9. PubMed ID: 18537959
[No Abstract] [Full Text] [Related]
6. Exenatide (exendin-4)-induced pancreatitis: a case report.
Denker PS; Dimarco PE
Diabetes Care; 2006 Feb; 29(2):471. PubMed ID: 16443920
[No Abstract] [Full Text] [Related]
7. Exenatide added to insulin. Beware the potentially serious adverse effects of exenatide.
Prescrire Int; 2013 Jun; 22(139):151. PubMed ID: 23885352
[No Abstract] [Full Text] [Related]
8. Effect of renal impairment on the pharmacokinetics of exenatide.
Linnebjerg H; Kothare PA; Park S; Mace K; Reddy S; Mitchell M; Lins R
Br J Clin Pharmacol; 2007 Sep; 64(3):317-27. PubMed ID: 17425627
[TBL] [Abstract][Full Text] [Related]
9. Acute exenatide (Byetta) poisoning was not associated with significant hypoglycemia.
Cohen V; Teperikidis E; Jellinek SP; Rose J
Clin Toxicol (Phila); 2008 Apr; 46(4):346-7. PubMed ID: 17852164
[No Abstract] [Full Text] [Related]
10. Exenatide and rare adverse events.
Ahmad SR; Swann J
N Engl J Med; 2008 May; 358(18):1970-1; discussion 1971-2. PubMed ID: 18456920
[No Abstract] [Full Text] [Related]
11. Exenatide-induced depression in a geriatric patient.
Kohen I; Lester P
Int J Geriatr Psychiatry; 2008 Apr; 23(4):443-4. PubMed ID: 18383195
[No Abstract] [Full Text] [Related]
12. Exenatide in type 2 diabetes.
Verzegnassi F; Chinello M
Lancet; 2010 Sep; 376(9746):1052-3; author reply 1053. PubMed ID: 20870094
[No Abstract] [Full Text] [Related]
13. Reply to Rees et al. Acute tubulointerstitial nephritis following treatment with exenatide.
Nandakoban H; Flack J; Furlong T
Diabet Med; 2013 Feb; 30(2):252. PubMed ID: 23088538
[No Abstract] [Full Text] [Related]
14. Response to Nandakoban et al. Acute tubulointerstitial nephritis following treatment with exenatide.
Rees DO; Price DE; Bain SC; Stephens JW
Diabet Med; 2013 Feb; 30(2):251-2. PubMed ID: 22998130
[No Abstract] [Full Text] [Related]
15. Exenatide: excessive weight loss.
Prescrire Int; 2011 Jan; 20(112):17. PubMed ID: 21462789
[No Abstract] [Full Text] [Related]
16. Exenatide in combination therapy: small study, big market, and many unanswered questions.
Malozowski S
Ann Intern Med; 2007 Apr; 146(7):527-8. PubMed ID: 17404355
[No Abstract] [Full Text] [Related]
17. A cohort study of acute pancreatitis in relation to exenatide use.
Dore DD; Bloomgren GL; Wenten M; Hoffman C; Clifford CR; Quinn SG; Braun DK; Noel RA; Seeger JD
Diabetes Obes Metab; 2011 Jun; 13(6):559-66. PubMed ID: 21320263
[TBL] [Abstract][Full Text] [Related]
18. Exenatide and acute pancreatitis.
Tripathy NR; Basha S; Jain R; Shetty S; Ramachandran A
J Assoc Physicians India; 2008 Dec; 56():987-8. PubMed ID: 19322980
[TBL] [Abstract][Full Text] [Related]
19. A case report of allergy to exenatide.
Pérez E; Martínez-Tadeo J; Callero A; Hernández G; Rodríguez-Plata E; García-Robaina JC
J Allergy Clin Immunol Pract; 2014; 2(6):822-3. PubMed ID: 25439386
[No Abstract] [Full Text] [Related]
20. Effect of immediate and prolonged GLP-1 receptor agonist administration on uric acid and kidney clearance: Post-hoc analyses of four clinical trials.
Tonneijck L; Muskiet MHA; Smits MM; Bjornstad P; Kramer MHH; Diamant M; Hoorn EJ; Joles JA; van Raalte DH
Diabetes Obes Metab; 2018 May; 20(5):1235-1245. PubMed ID: 29341461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
